Drug Profile
Research programme: Crohn's disease therapeutics - Genizon/Genentech
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Genizon BioSciences
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Crohn's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Crohn's-disease in USA